PANOPTES
Panoptes is a privately held biotech company focused on developing small molecule based therapies for the treatment of severe eye diseases.
PANOPTES
Industry:
Biotechnology Medical Pharmaceutical
Address:
Wiener Neustadt, Niederosterreich, Austria
Country:
Austria
Website Url:
http://www.panoptes-pharma.com
Status:
Active
Contact:
+43 1 8905697
Email Addresses:
[email protected]
Similar Organizations
TissueGene
TissueGene is a biopharmaceutical company focused on developing regenerative therapies for the treatment of various orthopedic disorders.
Official Site Inspections
http://www.panoptes-pharma.com
- Host name: 172.67.183.242
- IP address: 172.67.183.242
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Panoptes"
Panoptes Pharma - Innovationen in Ophthalmologie …
Panoptes Pharma Wir entwickeln innovative Therapien zur Behandlung von Augenkrankheiten und anderen Erkrankungen mit hohem medizinischem Bedarf. Wir sind bestrebt, die Lebensqualität von Patienten auf der ganzen Welt zu …See details»
Panoptes Pharma - Crunchbase Company Profile
Panoptes is a privately held biotech company focused on developing small molecule based therapies for the treatment of severe eye diseases with high …See details»
Organization | Panoptes Pharma
Panoptes Pharma Report issue For profit Phase 2 Founded: Vienna Austria (2013) Status: Acquired by Eyegate Pharmaceuticals, Inc. (2020) Organization Overview First Clinical Trial …See details»
Panoptes Pharma Company Profile 2024: Valuation, Investors
Information on acquisition, funding, cap tables, investors, and executives for Panoptes Pharma. Use the PitchBook Platform to explore the full profile.See details»
Panoptes Pharma - 2025 Company Profile - Tracxn
Panoptes Pharma is an acqui-hired company based in Vienna (Austria), founded in 2013. It operates as a Small molecule drugs to treat eye diseases. Panoptes Pharma has raised …See details»
Kiora Pharmaceuticals - Craft
Kiora Pharmaceuticals (formerly known as Panoptes Pharma) is a clinical-stage biotech company focused on developing small molecule-based therapies for the treatment of severe eye …See details»
Panoptes Pharma - VentureRadar
Panoptes intends to develop PaniJect and PaniDrop up to proof-of-concept studies in different indications in ophthalmology. Panoptes Pharma is developing products based on the novel …See details»
EyeGate Pharma Announces Transformative Acquisition of …
Dec 21, 2020 Dr. Franz Obermayr, co-founder and Chief Executive Officer of Panoptes, and EVP Clinical Development of EyeGate, said, “This acquisition by EyeGate, a clinical-stage …See details»
EyeGate Pharma Announces Acquisition of Panoptes Pharma
Dec 21, 2020 EyeGate Pharmaceuticals announced the acquisition of Panoptes Pharma, a privately-held clinical stage biotech company focused on developing a novel prSee details»
Panoptes’s Competitors, Revenue, Number of Employees, Funding …
Panoptes’s Profile, Revenue and Employees. Panoptes is a biotechnology company that develops and commercializes molecule-based novel therapies for the treatment of eye diseases. …See details»
Unternehmen - PANOPTES PHARMA
Über Panoptes Panoptes ist ein privates Biotech-Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Therapien auf Basis kleiner Moleküle zur Behandlung schwerer …See details»
Panoptes Pharma DMF, CEP, Written Confirmations, FDF
Panoptes is a privately held clinical stage biotech company focused on developing small molecule based therapies for the treatment of severe eye diseases with high unmet medical need. …See details»
Panoptes Pharma company information, funding & investors
Jul 1, 2013 Panoptes Pharma, developing innovative small molecule drugs to treat eye diseases with high unmet medical need. Here you'll find information about their funding, investors and …See details»
EyeGate Pharma Announces Transformative Acquisition of …
Dr. Franz Obermayr, co-founder and Chief Executive Officer of Panoptes, and EVP Clinical Development of EyeGate, said, “This acquisition by EyeGate, a clinical-stage public company …See details»
Kiora Pharmaceuticals Acquires Panoptes Pharma GES.M.B.H
Dec 21, 2020 Panoptes Pharma GES.M.B.H is a clinical stage biotech company focused on developing a novel proprietary small molecule for the treatment of severe eye diseases with a …See details»
Management Team - PANOPTES PHARMA
Franz Obermayr, Ph.D Vorstandsvorsitzender Dr. Franz Obermayr ist Mitbegründer und CEO von Panoptes Pharma. Zuvor war er Leiter der klinischen Entwicklung bei Nabriva Therapeutics …See details»
Can Innovative Small Molecule Drugs Revolutionize Eye Disease …
Oct 18, 2023 Key Takeaways: Panoptes Pharma is a Vienna-based startup creating innovative small molecule drugs to treat serious eye diseases. They are focusing on diseases with high …See details»
Panoptes: Ophthalmology company Panoptes Pharma successfully …
Nov 2, 2015 Panoptes Pharma Ges.m.b.H, announced today a financing round, led by aws Gründerfonds (aws Founders Fund) with participation from additional and existing investors. …See details»
Über uns - PANOPTES PHARMA
Panoptes ist ein privates Biotech-Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Therapien auf Basis kleiner Moleküle zur Behandlung schwerer …See details»
Über den Namen - PANOPTES PHARMA
Wir haben uns von Argus Panoptes inspirieren lassen, einem Riesen aus der griechischen Mythologie, der hundert Augen besaß. Er war ein sehr effektiver Wächter, da immer nur ein …See details»